EMT6 (mammary carcinoma)
EMT6 (ATCC® CRL-2755™) is a murine mammary carcinoma cell line derived from a transplanted hyperplastic alveolar nodule of a BALB/c mouse1. In syngeneic mice, EMT6 cells form tumors and spontaneous metastases, primarily to the lungs2,3. More recently, EMT6 has emerged as a valuable pre-clinical model for immuno-oncology studies of triple negative breast cancer. EMT6 tumors express PD-L1 and are moderately responsive to immunotherapies. Individual checkpoint inhibitors (anti-CTLA-4 or anti-PD-L1) generally have modest effect on tumor growth, while combination therapies exhibit greater success4-7, making EMT6 a beneficial model for combination therapy studies.
Imanis EMT6 Reporter Cell Lines
- Facilitate in vivo tracking using firefly luciferase (Fluc)
- Expedite precise post mortem analysis using enhanced green fluorescent protein (eGFP)
- Stably express* high-levels of reporter genes for bright detection of less cells.
* Imanis cell lines are generated by lentiviral vector transduction with self-inactivating (SIN) vectors8.
*The ATCC trademark and trade name and any and all ATCC catalog numbers are trademarks of the American Type Culture Collection.
- Rockwell et al. (1972) J Natl. Cancer Inst. 49: 735-749.
- Kresl et al. (1999) Tumor Biol. 20: 72-87.
- Viloria-Petit et al. (2009) PNAS. 106: 14028-14033.
- Lewis et al (2018) Oncoimmunology. 7: e1377873.
- Mariathasan et al. (2018) Nature. 554: 544-548.
- Xu et al. (2017) Clin Cancer Res. 23: 5869-5880.
- Jiao et al. (2017) Clin Cancer Res. 23: 3711-3720.
- Miyoshi et al. (1998) J Virol. 72: 8150-8157.